Signaling pathways in cancer: Holland and colleagues review recent developments in targeting pharmacodynamic biomarkers that could utilize PET of signal transduction pathways in cancer and suggest new strategies for optimizing this potential . . . . Page 1333

Axillary uptake in breast cancer: Song and colleagues determine standardized uptake values of metastatic axillary lymph nodes in patients with invasive ductal breast cancer to assess the pretreatment prognostic value of 18F-FDG PET/CT . . . . Page 1337

Colorectal liver metastases and PET/CT: Muralidharan and colleagues look at the predictive utility of metabolic measurements derived from 18F-FDG PET before liver resection and compare this with other prognostic scoring systems . . Page 1345

PET, PCC/PGL, and genotype: Rischke and colleagues explore the ability of 18F-DOPA PET to detect and stage pheochromocytomas/paragangliomas and ask whether specific genotypes correlate with tracer uptake . . . . . . . . . . . . . Page 1352

PET for temporal lobectomy: Theodore and colleagues assess the relative value of data from 5-HT1A PET and cerebral metabolic rate of glucose information from 18F-FDG PET for temporal lobectomy planning . . . . . . . . . . . . . Page 1375

Response to 177Lu-octreotate therapy: van Vliet and colleagues compare the response of bone lesions with that of soft tissues to treatment with 177Lu-octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors . . . . . . . Page 1359

PET and brain metastases: Galldiks and colleagues investigate the potential of 18F-FPET PET for differentiating local recurrent brain metastasis from radiation necrosis after radiation therapy . . . . . Page 1367

Rest–stress functional change: Karimi-Ashtiani and colleagues develop and validate a novel approach for automatic SPECT quantification of rest–stress myocardial motion and thickening changes . . . . Page 1392

CZT MPI in obesity: Fiechter and colleagues evaluate the effect of increased body mass on myocardial perfusion imaging quality using a latest-generation γ-camera with cadmium-zinc-telluride semiconductor detectors in patients with high body mass indices . . . . Page 1401

BAT activity in healthy men: Vrieze and colleagues use 18F-FDG PET/CT to examine the differential effects of an overnight fast and the postprandial state on brown adipose tissue activity . . . . . . Page 1407

Age effects on serotonin receptors: Matuskey and colleagues use an 11C-labeled tracer and PET to determine whether the availability of brain serotonin receptor 5-HT1B decreases with aging in healthy adults . . . . . . . . . . . . . Page 1411

PET/MRI workflow: Martinez-Möller and colleagues provide an educational overview of considerations relating to workflow, imaging protocols, and image analysis for
whole-body PET/MRI in oncology, based on early experience with an integrated PET/MRI scanner. Page 1415

**Imaging lymph node metastases:** Hall and colleagues develop and compare various dual-labeled monoclonal antibodies against the epithelial cell-adhesion molecule for both noninvasive and intraoperative detection of metastatic lymph nodes in prostate cancer. Page 1427

**Positron lymphography:** Thorek and colleagues investigate multimodal imaging in animal models using intradermal administration of $^{18}$F-FDG for combined diagnostic and intraoperative use, including the use of Cerenkov radiation to optically guide surgical resection of lymph nodes. Page 1438

**Site-specific protein radiolabeling:** Wållberg and colleagues describe a rapid technique for PET imaging of HER2-positive tumors in less than 1 h using a site-specific $^{11}$C-labeled Sel-tagged Affibody molecule. Page 1446

**Predosing for ADCs:** Boswell and colleagues evaluate in a mouse model a predosing strategy with unconjugated antibody to block antibody–drug conjugate uptake while preserving tumor uptake and efficacy. Page 1454

**Amphiphile-encapsulated nanoparticles:** Lee and colleagues develop and validate a method for modifying nanoparticles by encapsulation with specific ligand-conjugated amphiphiles and discuss the potential for multimodality and multispecific molecular imaging. Page 1462

**$^{18}$F-nifene kinetics:** Hillmer and colleagues use both kinetic modeling and graphical analysis techniques to analyze the in vivo kinetic properties of this $\alpha_4\beta_2^* \text{nicotinic acetylcholine receptor agonist PET radioligand.}$ Page 1471

**Radiometals and sst$_2$ antagonists:** Fani and colleagues explore whether chelated somatostatin antagonists are sensitive to radiometal modifications and look at explanations for this sensitivity. Page 1481

**SNMMI/ABNM statement on training:** Delbeke and colleagues provide context for and full text of the SNMMI/American Board of Nuclear Medicine joint position statement on optimizing training in nuclear medicine in the era of hybrid imaging. Page 1490

---

**ON THE COVER**

This image shows the lymphatics and the main nodal stations in a mouse after injection of $^{18}$F-FDG intracutaneously into the tail in a 3-dimensional PET/CT reconstruction.

See page 1440.